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Patho-physiological mechanismsIn the future, cardiovascular disease, together with depression, will be one of the leading causes of global disease
in the Western World. It is well known that depression is independently associated with a poor prognosis in
patients with ischemic heart disease.
Epidemiological studies suggest that in patients with coronary artery disease, depression symptoms identify
patients with higher risk of adverse cardiovascular outcomes, other studies maintain that depression symptoms
might inﬂuence the progression of coronary and peripheral atherosclerosis.
The deﬁned pathophysiological pathways which link depression and cardiovascular outcomes are not well rec-
ognized although variousmechanisms have been proposed to explain this association. Beyond traditional cardio-
vascular risk factors, autonomic nervous system, low grade of inﬂammation, platelet function, abnormal function
of the hypothalamic–pituitary–adrenal axis and genetic factors can adversely impact the endothelium and arte-
rial walls. Consequently, these mechanisms might be crucial factors in promoting and accelerating atherosclero-
sis and its complications due to plaque rupture and thrombosis. For these reasons, depression symptoms should
be considered as a new cardiac risk factor in the general population and in patients with coronary artery disease.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).“For some time, I do not know why, I lost all mymirth: I neglect my
exercises…”
As William Shakespeare described a depressed Hamlet, in the same
fashion we research the core aspects of depression: depressed mood,
loss of interest and pleasure, and fatigue, all apparently belong to the
purely psycho-social sphere, the correlations with the alteration of
homeostasis and man/environment allostasis and their inﬂuence on
the development of ischemic heart disease.
Scientiﬁc literature has abundantly shown how a percentage
between 14% and 47% of patients with ischemic heart disease suffer
from depressive symptoms, while the prevalence in the general popula-
tion ranges from 4 to 7% [1], these data, however, do not fully explain
the possible consecutio temporum between depression and coronary
artery disease.
However, the latest scientiﬁc ﬁndings, which are crucial to the
understanding of this etiological hypothesis, show how depression
had been developing for a long time in many patients, andmuch earliercina Specialistica, Diagnostica e
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nd Ltd. This is an open access article unthan the appearance of their acute coronary syndromes, so as to play a
negative prognostic role in the cardiac disease itself [2,3] (Fig. 1).
1. Pathophysiology of depression and cardiovascular disease
Various pathophysiological processes have been suggested to link
the depressive syndrome to an accelerated atherogenesis, that ultimate-
ly results in acute coronary syndromes. In addition to an unhealthy
lifestyle, several biological pathways may be involved that include dys-
regulation of the hypothalamic–pituitary–adrenal, abnormal autonomic
tone, modiﬁcations in platelet function, systemic immune activation
and endothelial dysfunction (Table 1).
1.1. Dysfunction of the autonomic nervous system
Depression is implicated in the dysregulation of the autonomic ner-
vous systemwhich in turn is implicated in the development of ischemic
heart disease.
In particular, from a clinical point of view, hyperactivity of the
sympathetic nervous system is associated with arterial hypertension, a
decreased heart rate variability, a decreased vagal tone and an increase
in the recovery time after stress, all factors related to increased cardio-
vascular mortality.
There is a directly proportional association between increased sym-
pathetic activity and the severity of depression.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Relative risk of traditional cardiovascular risk factors observed in the Framingham studies and relative danger of new cardiovascular risk factors from the data of themeta-analysis
Traditional Cardiovascular Risk Factors.
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determines a greater alteration in the sympatho-vagal balance com-
pared with patients with only ischemic heart disease, suggesting that
the effects of depression and ischemic heart disease are combined
with the variability of the heartbeat [4].
1.2. Inﬂammation
Inﬂammatory cytokines play a key role in the genesis and evolution
of atherosclerosis, unstable angina, acute myocardial infarction, ische-
mic heart disease and pathogenesis of chronic ischemic heart disease.
Depression has been linked to increased levels of inﬂammatory cyto-
kines (C-reactive protein, interleukin-1 and Inter china leu-6) [5,6].
This association has been documented in depressed patients with or
without cardiovascular disease. The presence of inﬂammation in de-
pressed patients predicts future cardiac events. However, it seems that
inﬂammation plays a minor role in mediating the effects of depression
on cardiovascular disease.
In fact, it has been proven that depression heralds cardiovascular
mortality in healthy subjects or with ischemic heart disease; but this
association was circa 20% lower if the values of inﬂammatory cytokines
were added to the multivariate analysis [7].
A recent study provides further evidence as to how depression is
associated with an increase in cardiovascular mortality by assuming
the value of the most signiﬁcant prognostic factor with respect to the
levels of C-reactive protein in patients with stable coronary artery
disease [8]. Several authors [9,10] have shown that depression isTable 1
Pathoetiological correlations between depression and
cardiovascular diseases.
Pathophysiological mechanisms
Autonomic nervous system alterations
Pro-inﬂammatory activation
Pro-coagulant factors activation
Endothelial dysfunction
Hypothalamic–pituitary–adrenal axis alterations
Genetic predisposition
Behavioral mechanisms
Smoking
Physical activity
Diet
Therapeutic adherencesigniﬁcantly associated with the metabolic syndrome, another risk fac-
tor for ischemic heart disease; inﬂammation and metabolic syndrome,
may play a synergistic role in determining a higher incidence of
coronary events through inﬂammatory cytokines.
1.3. Endothelial dysfunction
Endothelial dysfunction is involved in the altered control of vascular
tone, proliferation of smooth vascular muscle cells, increased platelet
aggregation, altered adhesive capacity of monocytes and leukocytes,
decrease in the release of anti-inﬂammatory factors and decreased
availability of nitric oxide.
All these factors account for the involvement of endothelial dysfunc-
tion in the clinical manifestations of atherosclerosis. Depression has
been associated with impaired endothelial function in healthy subjects
aswell as in subjects with atherosclerosis, and in patients with ischemic
heart disease. To conﬁrm this correlationwe have shown that treatment
of depressionwith selective inhibitors of the serotonin re-uptake inhib-
itors (SSRIs) improves endothelial function in patients with ischemic
heart disease and depression, providing further evidence that endothe-
lial dysfunction is altered in depressed patients with ischemic heart
disease [11].
1.4. Activity and increased platelet aggregation
Dysfunction and platelet aggregation activity are important factors
in the genesis and evolution of acute coronary syndromes, atherosclero-
sis and thrombosis.
Alterations in the aggregation capacity and activity of platelets in
patients with a major depression diagnosis are, hypothetically, related
to an increase in morbidity and a decrease in survival compared to the
general population.
Serotonin, an endogenous substancemainly involved inmood regu-
lation and implicated in the pathogenesis of depression, can play a key
role in the pathogenesis of myocardial ischemia through increased
platelet aggregation.
The catecholamines bind to the platelet receptor (Alfa-2a) inducing
an increase in the interplasmatic concentration of calcium, which in
turn causes the de-granulation of alpha and beta granules. The de-
granulation of alpha granules causes an increase in adhesion proteins
and pro-inﬂammatory cytokineswhile the beta granules release seroto-
nin, which leads to platelet aggregation and vasoconstriction [12].
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Depressed patients show an activation of the hypothalamic–pitui-
tary–adrenal axis [13,14]. Conﬁrming this, it has been observed that
almost 50% of patients with depression had high plasma cortisol levels
and that circa 50% of non-depressed patients did not respond to tests
for suppression of desametazone [15,16].
The involvement of the hypothalamic–pituitary–adrenal axis
dysregulation and its dysregulation exposes the depressed subject to a
series of metabolic disorders such as obesity, hypercholesterolemia,
hypertriglyceridemia, hypertension, glucose intolerance and inﬂamma-
tion, which are directly responsible for a correlationwith cardiovascular
disease.
1.6. Genetic predisposition
Among the possible causes that correlate depressionwith cardiovas-
cular disease, genetic alterations cannot be overlooked; in fact, studies
have been made on genetic polymorphisms that encode key elements
of the autonomic nervous system, the hypothalamic–pituitary–adrenal
axis, serotonin, for membrane transporters for serotonin and inﬂamma-
tion, elements that play a key role in depression and ischemic heart
disease.
Numerous studies are still underway to investigate the penetrance
of these polymorphisms.
1.7. Behavioral factors
Various behavioral factors are involved in the relationship between
depression and heart disease.
Depressed patients are less likely to change lifestyle, including diet,
ceasing to smoke, and physical activity.
In particular, there seems to be a special relationship between phys-
ical inactivity and depression: several scientiﬁc studies have shown that
active people are less depressed than sedentary people and inactive
people who become active are at lower risk of developing depression.
The failure of hygienic measures for the lives of these patients
contributes toworsening the prognosis. Moreover, according to a recent
meta-analysis, these patients are at double the risk of non-adherence to
prescribed treatment [17–20] and to the abuse of alcohol and smoking.
Finally, several studies show that depression signiﬁcantly correlates
with diabetes and obesity, known coronary risk factors.
2. Treatment of depression in cardiac patients
2.1. Pharmacological intervention
Several pharmacological interventions have been studied in de-
pressed patients with cardiovascular disease. The tricyclics (TCAs)
increase levels of serotonin, dopamine and norepinephrine in the
central nervous system. These drugs are effective for the treatment of
depression but should not be used in cardiac patients, given their ten-
dency to cause orthostatic hypotension, conduction abnormalities of
the stimulus with the appearance of arrhythmias and sudden death. In
fact, TCAs were associated with an increase in adverse cardiac events
in both healthy depressed subjects as well as in depressed patients
with cardiovascular disease [21].
SSRIs appear to be safe and effective in patients with acute coronary
syndrome and with chronic ischemic heart disease. These drugs act by
inhibiting the reuptake of serotonin and lead to increased levels of the
neurotransmitter in the synapse. SSRIs are safe in depressed patients
with acute coronary syndrome. A recent meta-analysis showed that
patients with ischemic heart disease treated with SSRIs have a better
prognosis than patients treated with placebo [22].
Little data is available on the efﬁcacy and safety of antidepressants in
the treatment of depressed patients with cardiovascular disease.2.2. Psychotherapeutic intervention
Psychotherapy is useful to improve depression but its usefulness in
improving prognosis in the depressed cardiac patient is still debatable.
3. Conclusions
Scientiﬁc evidence shows that depression is a risk factor for cardio-
vascular morbidity and mortality [23]. A more complete understanding
of themechanisms that mediate the link between depression and heart
disease could help develop treatments that improve the prognosis in
these patients. Despite the existence of effective and safe treatments
for depression in cardiac patients, the depression remains under-
recognized and under-treated in this subgroup of patients. Surely
depressed cardiac patients should be managed by a team of experts,
such as cardiologist, psychiatrist, psychologist and family physician
along with the family atmosphere. Only through this system can suit-
able programs be developed for the selection and treatment of de-
pressed cardiac patients.
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